Evolving Trends and Burden of Inflammatory Bowel Disease in Asia, 1990–2019: A Comprehensive Analysis Based on the Global Burden of Disease Study

Chen, Xuejie; Xiang, Xin; Xia, Weitong; Li, Xindi; Wang, Sidan; Ye, Shuyu; Tian, Li; Zhao, Lian; Ai, Feiyan; Shen, Zhaohua; Nie, Kai; Deng, Minzi; Wang, Xiaoyan

doi:10.1007/s44197-023-00145-w

Cited by 20 publications

(8 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Japan had the highest ASIR than the country, while Thailand (0.12 per 100,000) had the lowest ASIR in 2019. Japan experienced a significant increase in ASIR, from 11.22 per 100,000 population to 19.65 per 100,000 population from 1990 to 2019 ( 27 ). The age-standardized incidence of IBD, encompassing both Crohn’s disease (CD) and ulcerative colitis (UC), experienced a significant decrease in Poland from 2009 to 2020.…”

Section: Discussionmentioning

confidence: 99%

Study on the burden of digestive diseases among Chinese residents in the 21st century

Gong,

Zhang,

Wang

et al. 2024

Front. Public Health

View full text Add to dashboard Cite

BackgroundThe global burden of digestive diseases has increased in recent years. The study aims to comprehend the trend of incidence and death rates related to digestive diseases in China from 2000 to 2020.MethodsThe study collected data on digestive diseases and their causes, such as incidence rates, death rates, Years of Life Lost, Years Lived with Disability, Disability-Adjusted Life Years and estimated annual percentage change from the 2019 Global Burden of Disease website and the Chinese Health and Wellness Statistical Yearbook spanning. And we employed the age-period-cohort model to analyze the influence of age, period, and birth cohort on the trend of death rates associated with digestive diseases.ResultsIn contrast to the global burden of digestive disease, China experienced increases in the age-standardized incidence for inflammatory bowel disease, gallbladder and biliary diseases, as well as appendicitis from 2000 to 2019. The corresponding estimated annual percentage change for these diseases were 2.06, 1.74, and 0.99. Females showed a significantly higher incidence of digestive diseases, while males experienced a higher death rate. Moreover, individuals in the age groups under 5 years and over 60 years exhibited higher death rates than those in other age groups.ConclusionThe findings underscore the ongoing importance of digestive diseases as a substantial public health issue in China. Reducing the disease burden of IBD in China necessitates healthcare systems to enhance their infrastructure and personnel readiness, ensuring an equitable, affordable, and accessible distribution of care for IBD patients. To reduce the occurrence and mortality rates of digestive diseases in China, the government should promote the adoption of early screening policies for individuals under the 5 year and those above the 60 year. These policies should be accompanied by customized preventive measures.

show abstract

Section: Discussionmentioning

confidence: 99%

Study on the burden of digestive diseases among Chinese residents in the 21st century

Gong,

Zhang,

Wang

et al. 2024

Front. Public Health

View full text Add to dashboard Cite

show abstract

“…7,8 It is important to note that the incidence of IBD in China is as high as 1.74 per 100,000 person-years, 9 which can cause a significant disease burden on public health and the government. 10 Numerous studies have been conducted to explore the etiology of IBD, which is believed to be triggered by complex factors such as environmental contaminants, intestinal microbiota, the immune system, and genetic predispositions. 11 Environmental factors are becoming increasingly prominent.…”

Section: Introductionmentioning

confidence: 99%

“…Inflammatory bowel disease (IBD), which includes Crohn’s disease (CD) and ulcerative colitis (UC), − is a group of chronic, systemic, and nonspecific inflammatory bowel disorders that frequently relapse . The incidence of IBD has been increasing globally in recent years, including in China, due to industrialization and urbanization. , It is important to note that the incidence of IBD in China is as high as 1.74 per 100,000 person-years, which can cause a significant disease burden on public health and the government . Numerous studies have been conducted to explore the etiology of IBD, which is believed to be triggered by complex factors such as environmental contaminants, intestinal microbiota, the immune system, and genetic predispositions .…”

Section: Introductionmentioning

confidence: 99%

Serum Microcystin-LR Levels Linked with Risk of Inflammatory Bowel Disease: A Matched Case-Control Study in China

Chen,

Liu,

Liao

et al. 2024

Environ. Health

Self Cite

View full text Add to dashboard Cite

Microcystin-LR (MC-LR), the most prevalent and diverse cyanotoxin produced by harmful cyanobacterial blooms, has been linked to gastrointestinal toxicity. Therefore, we conducted a casecontrol study across four regions in China to investigate this relationship. Inflammatory bowel disease (IBD) cases (219) were matched with healthy controls (438) based on age and gender and conditional logistic regression models and Restricted cubic splines were used to evaluate the association between MC-LR exposure and IBD risk. We used quantitative real-time polymerase chain reaction to measure the expression levels of inflammatory factors. The levels of protein expression in the colorectum were determined using Western blotting (WB). Compared to the lowest quartile of serum MC-LR levels, the adjusted odds ratios and 95% confidence intervals (CI) for the highest quartiles of serum MC-LR levels were 5. 51 (2.70, 11.21). The RCS was shown the association between serum MC-LR levels and IBD risk was nonlinear (P nonlinear < 0.001). In the animal experiments, MC-LR resulted in colorectal injury via the PI3K/ AKT signaling pathway. Our study provides the evidence that serum MC-LR exposure is significantly associated with the risk of IBD in China. Animal study results indicate that MC-LR probably causes IBD via the PI3K/AKT signaling pathway.

show abstract

“…Inflammatory bowel disease, a chronic inflammatory disorder of the gastrointestinal tract marked by dysregulation of the intestinal immune response (1), encompasses two primary conditions: ulcerative colitis and Crohn's disease (2). The prevalence of IBD has surged worldwide with the advent of global industrialization, affecting not only developed nations like North America, Europe, Australia, and New Zealand, but also emerging regions in Asia and South America, as well as developing countries such as Brazil, South Korea, and China (3)(4)(5). Over the past decade, there has been a notable increase in the number of cases of Inflammatory Bowel Disease in China, rising from 1.72 cases per 100,000 to 3.35 cases per 100,000 in males and from 1.20 cases per 100,000 to 2.65 cases per 100,000 in females (5).…”

Section: Introductionmentioning

confidence: 99%

Association between 23 drugs and inflammatory bowel disease: a two-sample Mendelian randomization study

He,

Deng,

Huang

et al. 2024

Front. Med.

View full text Add to dashboard Cite

BackgroundInflammatory bowel disease (IBD) is a group of diseases characterized by chronic and recurrent inflammation of the gastrointestinal tract. The etiology of IBD remains multifaceted and poorly understood, resulting in limited treatment options that primarily target disease induction and remission maintenance. Thus, the exploration of novel therapeutic options for IBD among existing medications is advantageous. Mendelian randomization analysis (MR) serves as a valuable tool in investigating the relationship between drugs and diseases. In this study, MR analysis was employed to investigate the potential causal relationship between 23 approved drugs for the treatment of various diseases and IBD.MethodWe performed a two-sample MR analysis using publicly available genome-wide association study (GWAS) statistics. The inverse variance weighting (IVW) method was used as the main analysis method, supplemented by the remaining four methods (weighted median, MR Egger regression, simple and weighted models), and Meta-analysis was performed to expand the sample size to obtain a more reliable composite causal effect. Finally, Cochran’s Q statistic and the MR-Egger test for directed pleiotropy were applied to determine whether significant heterogeneity or directed pleiotropy existed.ResultsIn the main MR analysis (IVW), drugs with a negative causal association with the risk of IBD were immunosuppressant {OR (95% CI) = 0.7389 [0.6311–0.8651], p = 0.0046} and diabetes drugs {OR (95% CI) = 0.9266 [0.8876–0.9674], p = 0.0058}. A positive causal association with the risk of IBD was found for salicylic acid and derivatives {OR (95% CI) = 1.2737 [1.0778–1.5053], p = 0.0345}. Negative causal associations with UC risk were identified for immunosuppressants {OR (95% CI) = 0.6660 [0.5133–0.8640], p = 0.0169} and diabetes medications {OR (95% CI) = 0.9020 [0.8508–0.9551], p = 0.0046}; positive causal associations with UC risk were found for β-receptor blockers {OR (95% CI) = 1.1893 [1.0823–1.3070], p = 0.0046}. A negative causal association with the risk of CD was found for immunosuppressants {OR (95% CI) = 0.6957 [0.5803–0.8341], p = 0.0023}. There was no statistically significant association between the remaining 19 drugs and IBD and subtypes.ConclusionThis MR study provides evidence suggesting that immunosuppressants have a mitigating effect on the risk of IBD and demonstrate consistent efficacy in subtypes of ulcerative colitis (UC) and Crohn’s disease (CD). Additionally, diabetes medications show potential in reducing the risk of IBD, particularly in cases of UC, while β-blockers may elevate the risk of UC. Conversely, salicylic acid and its derivatives may increase the risk of IBD, although this effect is not consistently observed in the subtypes of the disease. These findings offer new insights into the prevention and management of IBD.

show abstract

Evolving Trends and Burden of Inflammatory Bowel Disease in Asia, 1990–2019: A Comprehensive Analysis Based on the Global Burden of Disease Study

Cited by 20 publications

References 61 publications

Study on the burden of digestive diseases among Chinese residents in the 21st century

Study on the burden of digestive diseases among Chinese residents in the 21st century

Serum Microcystin-LR Levels Linked with Risk of Inflammatory Bowel Disease: A Matched Case-Control Study in China

Association between 23 drugs and inflammatory bowel disease: a two-sample Mendelian randomization study

Contact Info

Product

Resources

About